Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx, Inc. (CDNA) reported its Q3 2022 financial results, achieving revenue of $79.4 million, a 5% increase year-over-year. The number of patient test results grew by 15%, totaling 46,500. Despite a strong GAAP gross margin of 73%, the net loss widened to $16.9 million, with a loss per share of $0.32. Adjusted EBITDA showed a loss of $2.5 million, contrasting with a gain in Q3 2021. The company has adjusted its 2022 revenue guidance to $320-$325 million due to a shift in payer mix.
CareDx, the Transplant Company, recently announced its participation in the ASN Kidney Week 2022, where it will present data on AlloSure Kidney and digital health solutions. This event, taking place from November 3-6 in Orlando, Florida, is an opportunity for CareDx to showcase its commitment to improving transplant patient care. The company will feature nine abstracts highlighting AlloSure's role in post-transplant surveillance, supported by findings from the groundbreaking ADMIRAL study, which demonstrated AlloSure's predictive capabilities for long-term graft survival.
CareDx, Inc. announced a study published in the Clinical Journal of the American Society of Nephrology demonstrating the efficacy of AlloSure® dd-cfDNA as a biomarker for early detection of allograft rejection and BK virus infection in pediatric kidney transplant patients. This independent study involved 57 patients and showed significant results, including an AUC of 0.82 for acute rejection detection. The findings emphasize AlloSure's potential for improving transplant outcomes through timely interventions, supporting CareDx's position as a leader in transplant innovation.
CareDx, Inc. (NASDAQ: CDNA) has congratulated C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving European Medicine Agency's draft qualification for the iBox Scoring System, a significant step in kidney transplant trials. The iBox system evaluates graft failure risk by assessing renal function and immunologic responses. CEO Reg Seeto expressed pride in collaborating with these groups to further transplant innovation.
CareDx, Inc. (NASDAQ: CDNA) will report its financial results for Q3 2022 on November 3, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties can listen by dialing 1-800-289-0438 for domestic calls or 1-323-794-2423 for international calls, using Conference ID: 2768596. The call will also be available via a live webcast on the company's investor relations website.
CareDx, Inc. (CDNA) announced a webinar in collaboration with the National Kidney Foundation and Honor the Gift Coalition to assist kidney transplant patients with Medicare enrollment related to the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, effective January 1, 2023. The webinar, titled "2023 Medicare Immunosuppressant Coverage: What Patients Need to Know," will take place on October 27, 2022, covering patient eligibility and coverage options. CareDx's initiative reflects its commitment to improving patient access to essential immunosuppressive treatments.
CareDx, Inc. (NASDAQ: CDNA) has announced its sponsorship at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Las Vegas from October 24-28. The company will present its innovative NGS HLA typing kits and chimerism monitoring solutions. CEO Reg Seeto emphasized their commitment to driving transplantation innovation. Key presentations include the unique hybrid capture approach of AlloSeq Tx17 for better donor-recipient matching, enhancing long-term allograft survival rates. The event highlights CareDx's leadership in precision medicine for transplant patients.
CareDx, Inc. (NASDAQ: CDNA) will host a symposium at the Heart Failure Society of America Annual Scientific Meeting in Washington, D.C., from September 30 to October 3, 2022. The event will focus on innovations in post-cardiac transplant care, particularly the AI Heart Platform with AiCAV™ for assessing cardiac allograft vasculopathy risk. Key presentations will address heart transplant surveillance and predictive models for patient outcomes. CareDx, a leader in precision medicine for transplant patients, emphasizes early interventions to enhance graft and recipient health.
CareDx, Inc. (NASDAQ: CDNA) announced a new study confirming that AlloMap, the only gene-expression profiling blood test for heart transplant rejection, significantly reduces pain and adverse events compared to heart biopsy. Conducted at Baylor University Medical Center, the study involved 43 patients and demonstrated that AlloMap's home testing option minimizes infection risk. The test has been FDA cleared since 2005 and is used in over 90% of U.S. heart transplant centers. The results support CareDx's commitment to enhancing patient experiences in transplant care.
